ADP Ribosylation Factor 5 (ARF5) is a member of the ARF family of small GTPases that play critical roles in intracellular membrane trafficking[1]. As a key regulator of vesicle formation and transport between the Golgi apparatus and endoplasmic reticulum (ER), ARF5 is essential for maintaining cellular homeostasis. Emerging research suggests that dysregulation of ARF5-mediated trafficking pathways contributes to the pathogenesis of neurodegenerative diseases, particularly Alzheimer's disease (AD)[2] and Parkinson's disease (PD)[3]. This page provides a comprehensive overview of ARF5's molecular function, expression patterns, disease associations, and therapeutic implications.
| ADP Ribosylation Factor 5 | |
|---|---|
| Gene Symbol | ARF5 |
| Full Name | ADP Ribosylation Factor 5 |
| Chromosome | 7q31.2 |
| NCBI Gene ID | [381](https://www.ncbi.nlm.nih.gov/gene/381) |
| OMIM | 103185 |
| Ensembl ID | ENSG00000104081 |
| UniProt ID | [P26447](https://www.uniprot.org/uniprot/P26447) |
| Protein Family | ARF GTPase family |
| Molecular Weight | ~20 kDa |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease |
ARF5 belongs to the ARF family of small GTP-binding proteins, which are structurally related to heterotrimeric G protein alpha subunits[4]. The ARF family comprises three classes: Class I (ARF1-3), Class II (ARF4-5), and Class III (ARF6), with ARF5 falling into Class II[5]. Like other ARF proteins, ARF5 functions as a molecular switch, cycling between an active GTP-bound state and an inactive GDP-bound state.
The protein consists of:
ARF5 shares approximately 85% sequence homology with ARF4, with which it is often functionally redundant in many cellular processes[6].
ARF5 activity is tightly regulated by:
Guanine nucleotide exchange factors (GEFs): ARF-GEFs catalyze the exchange of GDP for GTP, activating ARF5. The GBF1 (Golgi-specific brefeldin resistance factor 1) and BIG1/2 (Brettschneider et al.) families are the primary GEFs for Class II ARFs including ARF5[7].
GTPase activating proteins (GAPs): ARF-GAPs accelerate GTP hydrolysis, converting ARF5 to its inactive state. ARF1 and ARF5 are regulated by multiple GAPs including ARF-GAP1, ARF-GAP2, and ARF-GAP3[8].
Guanine nucleotide dissociation inhibitors (GDIs): GDI proteins extract ARF-GDP from membranes and maintain ARF proteins in soluble form, enabling their recycling[9].
ARF5 plays a central role in regulating anterograde and retrograde transport between the Golgi apparatus and endoplasmic reticulum[10]:
COPI vesicle formation: ARF5 activates coatomer complex (COPI) recruitment to Golgi membranes, initiating vesicle formation for intra-Golgi and Golgi-to-ER transport[11].
Golgi cisternal maturation: ARF5 GTPase activity contributes to the dynamic remodeling of Golgi cisternae during the maturation process[12].
Endosomal trafficking: ARF5 regulates transport between the trans-Golgi network (TGN) and endosomal compartments[13].
Beyond membrane trafficking, ARF5 influences lipid metabolism through activation of phosphatidylinositol 4-kinase (PI4K) and phospholipase D (PLD)[14]. These activities regulate phosphoinositide synthesis at the Golgi, phosphatidic acid production for membrane curvature, and lipid droplet dynamics.
ARF5 modulates actin polymerization at the Golgi apparatus through interaction with cofilin and the Arp2/3 complex[15]. This regulation affects Golgi morphology and positioning, vesicle trafficking speed, and cell polarization and migration.
ARF5 is ubiquitously expressed across human tissues, with highest expression in brain (particularly enriched in pyramidal neurons of the hippocampus and cortex), liver (high metabolic activity), and pancreas (insulin secretion involves intensive vesicle trafficking)[16].
In neurons, ARF5 localizes to the somatic Golgi apparatus, dendritic Golgi outposts, axon initial segment, and synaptic vesicle precursors.
ARF5 expression increases during brain development, peaking in early adulthood and showing decreased expression in aging[16:1]. This pattern aligns with the known decline in synaptic plasticity and membrane trafficking efficiency during normal aging.
Multiple mechanisms link ARF5 dysfunction to Alzheimer's disease pathogenesis[2:1]:
ARF5-mediated trafficking influences APP trafficking through the secretory pathway. Proper trafficking ensures appropriate amyloid-beta (Aβ) generation and clearance. ARF5 regulates the subcellular localization of β-secretase (BACE1), affecting amyloidogenic APP processing. Altered ARF5 activity can increase Aβ production by accelerating APP transport through the Golgi.
ARF5 contributes to tau pathology through ER-Golgi trafficking of tau, autophagy-lysosome pathway impairment leading to accumulation of hyperphosphorylated tau, and exosome secretion modulation for tau spread[17].
In Alzheimer's disease, ARF5 dysfunction contributes to synaptic deficits through impaired synaptic vesicle recycling, dysregulated postsynaptic receptor trafficking, and disrupted dendritic spine maintenance.
ARF5 involvement in Parkinson's disease centers on:
ARF5 plays a role in the intracellular trafficking of alpha-synuclein[3:1]. It regulates alpha-synuclein passage through the secretory pathway, impairs autophagic clearance of alpha-synuclein aggregates when dysfunctional, and modulates the release of toxic alpha-synuclein species via exosomes.
ARF5 influences mitochondrial dynamics through regulating mitochondrial transport along axons and dendrites, contributing to mitophagy initiation, and modulating ER-mitochondria contact sites critical for mitochondrial calcium and lipid exchange.
Several therapeutic strategies targeting ARF5-mediated pathways are under investigation:
Therapeutic approaches for PD include enhancing autophagic flux through ARF5 modulation, targeting ARF5-mediated mitochondrial quality control, and restoring dopamine release through ARF5 pathway normalization.
Casler J, et al. ARF GTPases in intracellular trafficking: implications for neurodegenerative disease. Journal of Cell Biology. 2024. ↩︎
Chen X, et al. Membrane trafficking dysfunction in Alzheimer's disease. Alzheimer's & Dementia. 2023. ↩︎ ↩︎
Taylor JP, et al. Alpha-synuclein trafficking and ARF GTPases in Parkinson's disease. Neurobiology of Disease. 2023. ↩︎ ↩︎
Dudley DT, et al. Structure and mechanism of ARF GTPases. Biochimica et Biophysica Acta. 2005. ↩︎
Pasqualato S, et al. Structural basis of ARF GTPase function. Nature Reviews Molecular Cell Biology. 2012. ↩︎
Goto M, et al. The ARF family: classification and functional analysis. Cellular and Molecular Life Sciences. 2010. ↩︎
Casanova JE, et al. ARF GTPase-activating proteins: regulation of ARF activity. Journal of Biological Chemistry. 2007. ↩︎
Randazzo PA, et al. ARF GAPs: regulators of ARF GTPases. Journal of Biological Chemistry. 2007. ↩︎
Serafini T, et al. ARF-GDI: a regulatory protein for ARF GTPases. Journal of Cell Biology. 1991. ↩︎
Schindler C, et al. ARF5 and Golgi function in eukaryotic cells. Traffic. 2009. ↩︎
Provin A, et al. COPI vesicle formation and ARF GTPases. Proceedings of the National Academy of Sciences. 2014. ↩︎
Glick BS, et al. Golgi cisternal maturation: a novel mechanism of ARF regulation. Journal of Cell Biology. 2014. ↩︎
Racca C, et al. ARF5 in endosomal trafficking pathways. Traffic. 2014. ↩︎
Jones DH, et al. ARF GTPases and lipid metabolism. Journal of Biological Chemistry. 2000. ↩︎
Liu W, et al. ARF5 and actin cytoskeleton dynamics in neurons. Journal of Neuroscience. 2015. ↩︎
Morrow AA, et al. ARF expression patterns in the aging human brain. Neurobiology of Aging. 2020. ↩︎ ↩︎
Mallucci G, et al. Tau secretion and prion-like spreading in neurodegeneration. Brain. 2023. ↩︎